Objective: γ-Hydroxybutyrate (GHB) has gained popularity as a drug of abuse. In the Netherlands the number of patients in treatment for GHB dependence has increased sharply. Clinical presentation of GHB withdrawal can be life threatening. We aim, through this overview, to explore the neurobiological pathways causing GHB dependency and withdrawal, and their implications for treatment choices. Methods: In this work we review the literature discussing the findings from animal models to clinical studies focused on the neurobiological pathways of endogenous but mainly exogenous GHB. Results: Chronic abuse of GHB exerts multifarious neurotransmitter and neuromodulator effects on γ-aminobutyric acid (GABA), glutamate, dopamine, serotonin, norepinephrine and cholinergic systems. Moreover, important effects on neurosteroidogenesis and oxytocin release are wielded. GHB acts mainly via a bidirectional effect on GABAB receptors (GABABR; subunits GABAB1 and GABAB2), depending on the subunit of the GIRK (G-protein-dependent ion inwardly rectifying potassium) channel involved, and an indirect effect of the cortical and limbic inputs outside the nucleus accumbens. GHB also activates a specific GHB receptor and β1-subunits of α4-GABAAR. Reversing this complex interaction of neurobiological mechanisms by the abrupt cessation of GHB use results in a withdrawal syndrome with a diversity of symptoms of different intensity, depending on the pattern of GHB abuse. Conclusion: The GHB withdrawal symptoms cannot be related to a single mechanism or neurological pathway, which implies that different medication combinations are needed for treatment. A single drug class, such as benzodiazepines, gabapentin or antipsychotics, is unlikely to be sufficient to avoid life-threatening complications. Detoxification by means of titration and tapering of pharmaceutical GHB can be considered as a promising treatment that could make polypharmacy redundant.

Keywords:
Neurobiology, γ-Hydroxybutyrate, Dependence, Withdrawal, Detoxification, Review
1.
Mamelak M: Gamma-hydroxybutyrate: an endogenous regulator of energy metabolism. Neurosci Biobehav Rev 1989;13:187-198.
2.
Laborit H: Sodium 4-hydroxybutyrate. Int J Neuropharmacol 1964;3:433-451.
3.
Kam P, Yoong F: Gamma-hydroxybutyric acid: an emerging recreational drug. Anaesthesia 1998;53:1195-1198.
4.
Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y: Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 2012;16:431-443.
5.
Addolorato G, Leggio L, Ferrulli A, Caputo F, Gasbarrini A: The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs 2009;18:675-686.
6.
EMCDDA: Annual Report 2012: The State of the Drugs Problem in Europe. Luxembourg, EU Publications Office, 2012.
7.
van Laar MW, Cruts AA, Van Ooyen-Houben MM, Meijer RF, Brunt T, Croes EA: Netherlands National Drug Monitor: NDM Annual Report 2011. Utrecht, Trimbos Institute, 2012.
8.
Guerreiro DF, Carmo AL, da Silva JA, Navarro R, Góis C: Club drugs. Review. Acta Med Port 2011;24:739-756.
9.
EMCDDA: European Drug Report: Trends and Developments. European Monitoring Centre for Drugs and Drug Addiction. Luxembourg, EU Publications Office, 2013.
10.
van Rooij AJ, Schoenmakers TM, van de Mheen D: Nationaal Prevalentie Onderzoek Middelengebruik 2009: Kerncijfers 2009. Rotterdam, Institute for Research in Addiction, 2011.
11.
CAM: Risicoschatting gamma-hydroxyboterzuur 2011. Rapport van het CAM; in: Coördinatiepunt Assessment en Monitoring nieuwe Drugs. Bilthoven, CAM, 2011.
12.
Bramness J, Haugland S: Abuse of γ-hydroxybutyrate. Tidsskr Nor Laegeforen 2011;131:2122-2125.
13.
Zovsec D, Smith S: Gamma-hydroxybutyrate (GHB) dependence and withdrawal; in Traub SJ (ed): UpToDate Online. 2012. http://www.uptodate.com/contents/gamma-hydroxybutyrate-ghb-dependence-and-withdrawal.
14.
Wisselink D, Mol A: GHB hulpvraag in Nederland: belangrijkste ontwikkelingen van de hulpvraag voor GHB problematiek in de verslavingszorg 2007-2012; in: Landelijk Alcohol en Drugs Informatie Systeem (LADIS) 2013. Houten, Stichting IVZ, 2013.
15.
Carter LP, Pardi D, Gorsline J, Griffiths R: Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend 2009;104:1-10.
16.
Wood D, Brailsford A, Dargan P: Acute toxicity and withdrawal syndromes related to γ-hydroxybutyrate (GHB) and its analogues γ- butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 2011;3:417-425.
17.
Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Megarbane B: The clinical toxicology of gamma-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 2012;50:458-470.
18.
Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE: Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 2011;29:319-332.
19.
Zvosec D, Smith S, Hall B: Three deaths associated with use of Xyrem. Sleep Med 2009;10:490-493.
20.
Roberts DM, Smith MW, Gopalakrishnan M, Whittaker G, Day RO: Extreme γ-butyrolactone overdose with severe metabolic acidosis requiring hemodialysis. Ann Emerg Med 2011;58:83-85.
21.
Snead O, Gibson KM: γ-Hydroxybutyric acid. N Engl J Med 2005;352:2721-2732.
22.
van Noorden MS, Kamal R, de Jong CA, Vergouwen AC, Zitman F: Gamma-hydroxybutyric acid (GHB) dependence and the GHB withdrawal syndrome: diagnosis and treatment (in Dutch). Ned Tijdschr Geneeskd 2010;154:A1286.
23.
van Amsterdam JG, Brunt T, McMaster M, Niesink R: Possible long-term effects of gamma-hydroxybutyric acid (GHB) due to neurotoxicity and overdose. Neurosci Biobehav Rev 2012;36:1217-1227.
24.
WHO Expert Committee on Drug Dependence: Critical Review Report. Thirty-Fifth Meeting Gamma-Hydroxybutyric Acid (GHB). Hammamet, World Health Organisation, 2012.
25.
Tunnicliff G: Sites of action of gamma-hydroxybutyrate (GHB) - a neuroactive drug with abuse potential. Clin Toxicol 1997;35:581-590.
26.
Wong C, Gibson K, Snead O: From the street to the brain: neurobiology of the recreational drug γ-hydroxybutyric acid. Trends Pharmacol Sci 2004;25:29-34.
27.
Andresen H, Aydin BE, Mueller A, Iwersen-Bergmann S: An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results. Drug Test Anal 2011;3:560-568.
28.
Le Beau M, Miller M, Levine B: Effect of storage temperature on endogenous GHB levels in urine. Forensic Sci Int 2001;119:161-167.
29.
Lyon R, Johnston SM, Watson DG, McGarvie G, Ellis E: Synthesis and catabolism of gamma-hydroxybutyrate in SH-SY5Y human neuroblastoma cells: role of the aldo-keto reductase AKR7A2. J Biol Chem 2007;282:25986-25992.
30.
Kapoor P, Deshmukh R, Kukreja I: GHB acid: a rage or reprieve. J Adv Pharm Technol Res 2013;4:173-178.
31.
Snead OC 3rd, Furner R, Liu CC: In vivo conversion of gamma-aminobutyric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain. Studies using stable isotopes. Biochem Pharmacol 1989;38:4375-4380.
32.
Abanades S, Farre M, Segura M, Pichini S, Barral D, Pacifici R, Pellegrini M, Fonseca F, Langohr K, De La Torre R: Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann NY Acad Sci 2006;1074:559-576.
33.
Muller C, Viry S, Miehe M, Andriamampandry C, Aunis D, Maitre M: Evidence for a γ- hydroxybutyrate (GHB) uptake by rat brain synaptic vesicles. J Neurochem 2002;80:899-904.
34.
Gobaille S, Hechler V, Andriamampandry C, Kemmel V, Maitre M: γ-Hydroxybutyrate modulates synthesis and extracellular concentration of γ-aminobutyric acid in discrete region in vivo in rat brain regions. J Pharmacol Exp Therap 1999;209:303-309.
35.
Palantini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, Gallimberti L, Gessa GL, Ferrara S: Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993;45:353-356.
36.
Zvosec DL, Smith SW, McCutcheon R, Spillane J: Adverse events, including death, associated with the use of 1,4 butanediol. N Engl J Med 2001;344:87-94.
37.
Morse BL, Felmlee MA, Morris ME: Gamma-hydroxybutyrate blood/plasma partitioning: effect of physiologic pH on transport by monocarboxylate transporters. Drug Metab Dispos 2012;40:64-69.
38.
Wang Q, Lu Y, Morris ME: Monocarboxylate transporter (MCT) mediates the transport of gamma-hydroxybutyrate in human kidney HK-2 cells. Pharm Res 2007;24:1067-1078.
39.
Morse BL, Vijay N, Morris ME: Gamma-hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose. Mol Pharmacol 2012;82:226-235.
40.
Ottani A, Saltini S, Bartiromo M, Zaffe D, Renzo Botticelli A, Ferrari A, Bertolini A, Genedani S: Effect of gamma-hydroxybutyrate in two rat models of focal cerebral damage. Brain Res 2003;986:181-119.
41.
Kemmel V, Klein C, Dembele D, Jost B, Taleb O, Aunis D, Mensah-Nyagan AG, Maitre M: A single acute pharmacological dose of gamma-hydroxybutyrate (GHB) modifies multiple gene expression patterns in rat hippocampus and frontal cortex. Physiol Genomics 2010;41:146-160.
42.
Wendt G, Kemmel V, Patte-Mensah C, Uring-Lamert BE, Schmitt MJ, Mensah-Nyagan AG: Gamma-hydroxybutyrate, acting through an anti-apoptotic mechanism, protects native and amyloid-precursor-protein-transfected neuroblastoma cells against oxidative stress-induced death. Neuroscience 2014;263:203-215.
43.
Tokumura A, Tanaka T, Yotsumoto T, Tsukatani H: Identification of sn-2-ω-hydroxycarboxylate-containing phospholipids in a lipid extract from bovine brain. Biochem Biophys Res Commun 1991;177:466-473.
44.
Mamelak M: Narcolepsy and depression and the neurobiology of gamma-hydroxybutyrate. Prog Neurobiol 2009;89:193-219.
45.
Pedraza C, Garciá FB, Navarro J: Neurotoxic effects induced by gamma-hydroxybutyric acid (GHB) in male rats. Int J Neuropsychopharmacol 2009;12:1165-1177.
46.
Sircar R, Basak A, Sircar D, Wu L: Effects of gamma-hydroxybutyric acid on spatial learning and memory in adolescent and adult female rats. Pharmacol Biochem Behav 2010;96:187-193.
47.
Sircar R, Wu L, Reddy K, Sircar D, Basak A: GHB-induced cognitive deficits during adolescence and the role of NMDA receptor. Curr Neuropharmacol 2011;9:240-243.
48.
van Nieuwenhuijzen P, Kashem MA, Matsumoto I, Hunt G, McGregor I: A long hangover from party drugs: residual proteomic changes in the hippocampus of rats 8 weeks after gamma-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. Neurochem Int 2010;56:871-877.
49.
Mamelak M, Black J, Montplaisir J, Ristanovic R: A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004;27:1327-1334.
50.
Lapierre O, Montplaisir J, Lamarre M, Bedard MA: The effect of gamma-hydroxybutyrate on nocturnal and diurnal sleep of normal subjects: further considerations on REM sleep-triggering mechanisms. Sleep 1990;13:24-30.
51.
Peterson MJ, Benca RM: Sleep in mood disorders. Psychiatr Clin North Am 2006;29:1009-1032.
52.
Felmlee MA, Roiko SA, Morse B, Morris M: Concentration-effect relationships for the drug of abuse gamma-hydroxybutyric acid. J Pharmacol Exp Ther 2010;333:764-771.
53.
Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J: Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol 2010;21:332-342.
54.
Castelli M: A review of pharmacology of NCS-382, a putative antagonist of γ-hydroxybutyric acid (GHB) receptor. CNS Drug Reviews 2004;10:243-260.
55.
Crunelli V, Emri Z, Leresche N: Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol 2006;6:44-52.
56.
Bay T, Eghorn LF, Klein AB, Wellendorph P: GHB receptor targets in the CNS: focus on high-affinity binding sites. Biochem Pharmacol 2014;87:220-228.
57.
van Nieuwenhuijzen PS, McGregor IS: Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry. Drug Alcohol Depend 2009;103:137-147.
58.
Connelly WM, Errington AC, Crunelli V: γ-Hydroxybutyric acid (GHB) is not an agonist of extrasynaptic GABAA receptors. PLoS One 2013;8:e79062.
59.
Carai MA, Colombo G, Brunetti G, Melis S, Serra S, Vacca G, Mastinu S, Pistuddi AM, Solinas C, Cignarella G, Gessa GL: Role of GABAB receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid. Eur J Pharmacol 2001;428:315-321.
60.
Gervasi N, Monnier Z, Vincent P, Paupardin-Tritsch D, Hughes SW, Crunelli V, Leresche N: Pathway-specific action of gamma-hydroxybutyric acid in sensory thalamus and its relevance to absence seizures. J Neurosci 2003;23:11469-11478.
61.
Carai M, Lobina C, Maccioni P, Cabras C, Colombo G, Gessa GL: γ-Aminobutyric acid B (GABAB)-receptor mediation of different in vivo effects of γ-butyrolactone. J Pharmacol Sci 2008;106:199-207.
62.
Molnár T, Antal K, Nyitrai G, Emri Z: Gamma-hydroxybutyrate (GHB) induces GABAB receptor independent intracellular Ca2+ transients in astrocytes, but has no effect on GHB or GABAB receptors of medium spiny neurons in the nucleus accumbens. Neuroscience 2009;162:268-281.
63.
Carter LP, Chen W, Wu H, Mehta A.K, Hernandez RJ, Ticku MK, Coop A, Koek W, France CP: Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV). Drug Alcohol Depend 2005;78:91-99.
64.
Maitre M, Kemmel V, Andriamampandry C, Gobaille S, Aunis D: The role of γ-hydroxybutyrate in brain function; in Tunnicliff G, Cash, C (eds): Gamma-Hydroxybutyrate: Molecular, Functional and Clinical Aspects. London/New York, Taylor & Francis, 2002, pp 236-247.
65.
Koek W, Flores LR, Carter LP, Lamb RJ, Chen W, Wu H: Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in pigeons: involvement of diazepam-sensitive and -insensitive GABAA receptors and of GABAB receptors. J Pharmacol Exp Ther 2004;308:904-911.
66.
Absalom N, Eghornb LF, Villumsenb IS, Karima N, Bayb T, Olsen JV, Knudsend GM, Bräuner-Osborneb H, Frølundb B, Clausenb RP: α4βδ GABAA receptors are high-affinity targets for γ-hydroxybutyric acid (GHB). Neuroscience 2012;109:13404-13409.
67.
Nasrallah F, Maher A, Hanrahan J, Balcar V, Rae C: Gamma-hydroxybutyrate and the GABAergic footprint: a metabolomic approach to unpicking the actions of GHB. J Neurochem 2010;115:58-67.
68.
Brenneisen R: Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 2004;28:625-630.
69.
Abanades S, Farre M, Barral D, Torrens M, Closas N, Langohr K. Pastor A, de la Torre R: Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol 2007;27:625-638.
70.
Weerts EM, Goodwin AK, Griffiths RR, Brown PR, Froestl W, Jakobs C, Gibson KM: Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons. Psychopharmacology (Berl) 2005;179:678-687.
71.
Cook H: The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 2003;41:131-135.
72.
Addolorato G, Castelli E, Stefanini GF, Casella G, Caputo F, Marsigli L: An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Alcohol Alcohol 1996;31:341-345.
73.
Gallimberti L, Ferri M, Ferrara SD, Fadda F, Gessa G: Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res 1992;16:673-676.
74.
Gallimberti L, Spella MR, Soncini CA, Gessa GL: Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol 2000;20:257-262.
75.
Goodwin A, Kaminski B, Griffiths R, Ator N, Weerts E: Intravenous self-administration of gamma-hydroxybutyrate (GHB) in baboons. Drug Alcohol Depend 2011;114:217-224.
76.
Wojtowicz J: Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and γ-butyrolactone: a case report and systematic review. CJEM 2008;10:69-74.
77.
Dyer J, Roth B, Hyma BA: Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001;37:147-153.
78.
Perez E, Chu J, Bania T: Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann Emerg Med 2006;48:219-220.
79.
de Jong C, Kamal R, Dijkstra BA, de Haan HA: Gamma-hydroxybutyrate detoxification by titration and tapering. Eur Addict Res 2012;18:40-45.
80.
Craig K, Gomez HF, McManus JL, Bania T: Sever gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000;18:65-70.
81.
Pistis M, Muntoni A, Pillolla G, Perra S, Cignarella G, Melis M, Gessa GL: Gamma-hydroxybutyric acid (GHB) and the mesoaccumbens reward circuit: evidence for GABAB receptor-mediated effects. Neuroscience 2005;131:465-474.
82.
Matgorzata F: GABAB receptors in drug addiction. Pharmacol Rep 2008;60:755-770.
83.
Kalivas PW, Lalumiere RT, Knackstedt L, Shen H : Glutamate transmission in addiction. Neuropharmacology 2009;56(suppl 1): 169-173.
84.
Kalivas P, Volkow N: The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162:1403-1413.
85.
Cruz H, Ivanova T, Lunn M, Stoffel M, Slesinger P, Luscher C: Bi-directional effects of GABAB receptor agonists on the mesolimbic dopamine system. Nat Neurosci 2004;7:153-159.
86.
Koek W, France C: Cataleptic effects of gamma-hydroxybutyrate (GHB) and baclofen in mice: mediation by GABAB receptors, but differential enhancement by N-methyl-D-aspartate (NMDA) receptor antagonists. Psychopharmacology (Berl) 2008;199:191-198.
87.
Carter LP, Wu H, Chen W: Novel gamma-hydroxybutyric acid (GHB) analogs share some, but not all, of the behavioral effects of GHB and GABAB receptor agonists. J Pharmacol Exp Ther 2005;313:1314-1323.
88.
Hechler V, Ratomponirina C, Maitre M: Gamma-hydroxybutyrate conversion into GABA induces displacement of GABAB binding that is blocked by valproate and ethosuximide. J Pharmacol Exp Ther 1997;281:753-760.
89.
Mathivet P, Bemasconi R, De Barry J, Marescaux C, Bittiger H: Binding characteristics of γ-hydroxybutyric acid as a weak but selective GABAB receptor agonist. Euro J Pharmacol 1997;321:67-75.
90.
Hensler J, Advani T, Burke TF, Cheng K, Rice KC, Koek W: GABAB receptor-positive modulators: brain region-dependent effects. J Pharmacol Exp Ther 2012;340:19-26.
91.
Queva C, Bremner-Danielsen M, Edlund A, Ekstrand AJ, Elg S, Erickso S, Johansson T, Lehmann A, Mattsson JP: Effects of GABA agonists on body temperature regulation in GABAB(1)-/- mice. Br J Pharmacol 2003;140:315-322.
92.
Kaupmann K: Specific gamma-hydroxybutyrate- binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABAB1-deficient mice. Eur J Neurosci 2003;18:2722-2730.
93.
Labouèbe G, Lomazzi M, Cruz HG, Creton C, Luján R, Li M, Yanagawa Y, Obata K, Watanabe M, Wickman K, Boyer SB, Slesinger PA, Lüscher C: RGS2 modulates coupling between GABAB receptors and GIRK channels in dopamine neurons of the ventral tegmental area. Nat Neurosci 2007;10:1559-1568.
94.
Mark M, Herlitze S: G-protein mediated gating of inward-rectifier K+ channels. Eur J Biochem 2000;267:5830-5836.
95.
Wickman K, Karschin C, Karschin A, Picciotto MR, Clapham DE: Brain localization and behavioral impact of the G-protein-gated K+ channel subunit GIRK4. Neurosci 2000;20:5608-5615.
96.
Lüscher C, Jan LY, Stoffel M, Malenka R, Nicoll RA: G-protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron 1997;19:687-695.
97.
Drasbek K, Christensen J, Jensen K: Gamma-hydroxybutyrate - a drug of abuse. Acta Neurol Scand 2006;114:145-156.
98.
Hédou G, Chasserot-Golaz S, Kemmel V, Gobaille S, Roussel G, Artault JC, Andriamampandry C, Aunis D, Maitre M: Immunohistochemical studies of the localization of neurons containing the enzyme that synthesizes dopamine, GABA, or gamma-hydroxybutyrate in the rat substantia nigra and striatum. J Comp Neurol 2000;426:549-560.
99.
Hechler V, Gobaille S, Maitre M: Selective distribution pattern of γ-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography. Brain Res 1992;572:345-348.
100.
Ferraro L, Tanganelli S, O'Connor WT, Francesconi W, Loche A, Gessa GL, Antonelli T: γ-Hydroxybutyrate modulation of glutamate levels in the hippocampus: an in vivo and in vitro study. J Neurochem 2001;78:929-939.
101.
Aizawa M, Ito Y, Fukuda H: Roles of gamma-aminobutyric acid B (GABAB) and gamma-hydroxybutyric acid receptors in hippocampal long-term potentiation and pathogenesis of absence seizures. Biol Pharm Bull 1997;20:1066-1070.
102.
Banerjee PK, Snead OC 3rd: Presynaptic gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acid B (GABAB) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GHB. J Pharmacol Exp Ther 1995;273:1534-1543.
103.
Loonen AJ: Het beweeglijke Brein. Haarlem, Mension, 2004.
104.
Kahn I, Shohamy D: Intrinsic connectivity between the hippocampus, nucleus accumbens, and ventral tegmental area in humans. Hippocampus 2013;23:187-192.
105.
Kauer JA, Malenka RC: Synaptic plasticity and addiction. Nature Rev Neurosci 2007;11:844-858.
106.
Carter LP, Koek W, France C: Behavioral analyses of GHB: receptor mechanisms. Pharmacol Ther 2009;121:100-114.
107.
Kalivas P: The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009;10:561-572.
108.
Li Q, Kuhn CM, Wilson WA, Lewis DV: Effects of gamma-hydroxybutyric acid on inhibition and excitation in rat neocortex. Neuroscience 2007;150:82-92.
109.
Molnár T, Heja L, Emri Z, Simon A, Nyitrai G, Pal I, Kardos J: Activation of astroglial calcium signaling by endogenous metabolites succinate and gamma-hydroxybutyrate in the nucleus accumbens. Front Neuroenergetics 2011;3:7.
110.
Wang F, Smith NA, Xu Q, Fujita T, Baba A, Matsuda T, Takano T, Bekar L, Nedergaard M: Astrocytes modulate neural network activity by Ca2+-dependent uptake of extracellular K+. Sci Signal 2012;5(218):ra26.
111.
Gobaille S, Schleef C, Hechle V, Viry S, Aunis D, Maitre M: Gamma-hydroxybutyrate increases tryptophan availability and potentiates serotonin turnover in rat brain. Life Sci 2002;70:2101-2112.
112.
Hedner T, Lundborg P: Effect of gamma-hydroxybutyric acid on serotonin synthesis, concentration and metabolism in the developing rat brain. J Neural Transm 1983;57:39-48.
113.
Pardridge W, Fierer G: Transport of tryptophan into brain from the circulating albumin-bound pool in rats and in rabbits. J Neurochem 1990;54:971-976.
114.
Burman KJ, Ige AO, White JH, Marshall F, Pangalos MN, Emson P, Minson JB, Llewellyn-Smith IJ: GABAB receptor subunits, R1 and R2, in brainstem catecholamine and serotonin neurons. Brain Res 2003;970:35-46.
115.
Ferré S, Artigas F: Dopamine D2 receptor-mediated regulation of serotonin extracellular concentration in the dorsal raphe nucleus of freely moving rats. J Neurochem 1993;61:772-775.
116.
Abellan MT, Jolas T, Aghajanian GK, Artigas F : Dual control of dorsal raphe serotonergic neurons by GABAB receptors. Electrophysiological and microdialysis studies. Synapse 2000;36:21-34.
117.
Szabo S, Gold MS, Goldberger BA, Blier P: Effects of sustained gamma-hydroxybutyrate treatments on spontaneous and evoked firing activity of locus coeruleus norepinephrine neurons. Biol Psychiatry 2004;55:934-939.
118.
Giorgetti M, Bacciottini L, Giovannini MG, Colivicchi MA, Goldfarb J, Blandina P: Local GABAergic modulation of acetylcholine release from the cortex of freely moving rats. Eur J Neurosci 2000;12:1941-1948.
119.
Nava F, Carta G, Bortolato M, Gessa GL: γ-Hydroxybutyric acid and baclofen decrease extracellular acetylcholine levels in the hippocampus via GABA receptors. Eur J Pharmacol 2001;430:261-263.
120.
Volpi R, Chiodera P, Caffarra P: Muscarinic cholinergic mediation of the GH response to gamma-hydroxybutyric acid: neuroendocrine evidence in normal and Parkinsonian subjects. Psychoneuroendocrinology 2000;25:179-185.
121.
Vescovi P, Coiro V: Different control of GH secretion by gamma-amino- and gamma-hydroxy-butyric acid in 4-year abstinent alcoholics. Drug Alcohol Depend 2001;61:217-221.
122.
Bosch O, Quednow BB, Seifritz E, Wetter TC: Reconsidering GHB: orphan drug or new model antidepressant? J Psychopharmacol 2012;26:618-628.
123.
Van Cauter E, Plat L, Scharf MB, Leproult R, Cespedes S, L'Hermite-Balériaux M, Copinschi G: Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men. J Clin Invest 1997;100:745-753.
124.
Camacho A, Matthews SC, Murray B, Dimsdale JE: Use of GHB compounds among college students. Am J Drug Alcohol Abuse 2005;31:601-607.
125.
Mellon S, Griffen L: Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab 2002;13:35-43.
126.
Koek W, Carter LP, Lamb RJ, Chen W, Wu H, Coop A, France C: Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in rats discriminating GHB from baclofen and diazepam. J Pharmacol Exp Ther 2005;314:170-179.
127.
Barbaccia ML, Carai MA, Colombo G, Lobina C, Purdy RH, Gessa G: Endogenous gamma-aminobutyric acid (GABAA) receptor active neurosteroids and the sedative/hypnotic action of gamma-hydroxybutyric acid (GHB): a study in GHB-S (sensitive) and GHB-R (resistant) rat lines. Neuropharmacology 2005;49:48-58.
128.
Barbaccia ML, Colombo G, Affricano D, Carai MA, Vacca G, Melis S, Purdy RH, Gessa GL: GABAB receptor-mediated increase of neurosteroids by γ-hydroxybutyric acid. Neuropharmacology 2002;42:782-791.
129.
Greiner C, Röhl JE, Gorji A, Wassmann H, Speckmann EJ: Different actions of gamma-hydroxybutyrate: a critical outlook. Neurol Res 2003;25:25:759-763.
130.
Hechler V, Gobaille S, Bourguignon JJ, Maitre M: Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study. J Neurochem 1991;56:938-944.
131.
Mahler S, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G: Multiple roles for orexin/hypocretinin addiction. Prog Brain Res 2012;198:79-121.
132.
Bayard S, Dauvilliers YA: Reward-based behaviors and emotional processing in human with narcolepsy-cataplexy. Front Behav Neurosci 2013;7:50.
133.
Boutrel B, Steiner N, Halfon O: The hypocretins and the reward function: what have we learned so far? Front Behav Neurosci 2013;7:59.
134.
Bell J, Collins R: Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction 2011;106:442-447.
135.
McDonough M, Kennedy N, Glasper A, Bearn J: Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75:3-9.
136.
Maitre M, Andriamampandry C, Kemmel V, Schmidt C, Hodé Y, Hechler V, Gobaille S: Gamma-hydroxybutyric acid as a signaling molecule in brain. Alcohol 2000;20:277-283.
137.
Schmidt-Mutter C, Muller C, Zwiller J: Gamma-hydroxybutyrate and cocaine administration increases mRNA expression of dopamine D1 and D2 receptors in rat brain. Neuropsychopharmacology 1999;21:662-669.
138.
van Noorden MS, van Dongen LC, Zitman FG, Vergouwen TA: Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen Hosp Psychiatry 2009;31:394-396.
139.
Wong CG, Chan KF, Gibson KM, Snead O: Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol Rev 2004;23:3-20.
140.
Volkow ND, Wang, GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N: Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997;386:830-833.
141.
Goldstein RZ, Volkow ND: Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002;159:1642-1652.
142.
Asensio S, Romero MJ, Romero FJ, Wong C, Alia-Klein N, Tomasi D, Wang G, Telang F, Volkow ND, Goldstein RZ: Striatal dopamine D2 receptor availability predicts the thalamic and medial prefrontal responses to reward in cocaine abusers three years later. Synapse 2010;64:397-402.
143.
Miotto K, Roth B: GHB Withdrawal Syndrome. Austin, Texas Commission on Alcohol and Drug Abuse (TCADA), 2001.
144.
Karreman M, Moghaddam B: The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J Neurochem 1996;66:589-598.
145.
Vilke GM, Bozeman WP, Dawes DM, Demers G, Wilson MP: Excited delirium syndrome (ExDS): treatment options and considerations. J Forensic Leg Med 2012;19:117-121.
146.
Stijnenbosch PJ, Zuketto C, Beijaert PJ, Maat A: GHB withdrawal delirium (in Dutch). Ned Tijdschr Geneeskd 2010;154:A1086.
147.
Supady A, Schwab T, Busch HJ: ‘Liquid ecstasy': γ-butyrolactone withdrawal delirium with rhabdomyolysis and dialysis dependent renal failure. Dtsch Med Wochenschr 2009;134:935-937.
148.
Bhattacharya I, Watson F, Bruce M: A case of γ-butyrolactone associated with severe withdrawal delirium and acute renal failure. Eur Addict Res 2011;17:169-171.
149.
Tarabar AF, Nelson LS: The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev 2004;23:45-49.
150.
Eiden C, Capdevielle D, Deddouche C, Boulenger JP, Blayac JP, Peyrière H: Neuroleptic malignant syndrome-like reaction precipitated by antipsychotics in a patient with γ-butyrolactone withdrawal. J Addict Med 2011;5:302-303.
151.
Ghio L, Cervetti A, Respino M, Belvederi Murri M, Amore M: Management and treatment of γ-butyrolactone withdrawal syndrome: a case report and review. J Psychiatr Pract 2014;20:294-300.
152.
Nardou R, Yamamoto S, Bhar. A, Burnashev N, Ben-Ari Y, Khalilov I: Phenobarbital but not diazepam reduces AMPA/kainite receptor mediated currents and exerts opposite actions on initial seizures in the neonatal rat hippocampus. Front Cell Neurosci 2011;5:16.
153.
Crunelli V, Emri Z, Leresche N: Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol 2006;6:44-52.
154.
LeTourneau J, Hagg D, Smith S: Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care 2008;8:430-433.
155.
Kamal R, van Noorden MS, Dijkstra BA, Mauritz R, de Jong C: A case series of pharmaceutical gamma-hydroxybutyrate in 3 patients with severe benzodiazepine-resistant gamma-hydroxybutyrate withdrawal in the hospital. Psychosomatics 2015;56:404-409.
156.
Dijkstra B, De Weert-van Oene GH, Verbrugge CA, De Jong C: GHB Detoxificatie met farmaceutische GHB. Eindrapportage van de monitoring van DeTiTap® in de Nederlandse verslavingszorg. Nijmegen, Nijmegen Institute for Scientist-Practitioners in Addiction, 2013.
157.
Oades R: Dopamine may be ‘hyper' with respect to noradrenaline metabolism, but ‘hypo' with respect to serotonin metabolism in children with attention-deficit hyperactivity disorder. Behav Brain Res 2002;130:97-102.
158.
Winstanley C, Theobald DE, Dalley JW, Robbins T: Interactions between serotonin and dopamine in the control of impulsive choice in rats: therapeutic implications for impulse control disorders. Neuropsychopharmacology 2005;30:669-682.
159.
Steeves T, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, Van Eimeren T, Rusjan P, Houle S, Strafella AP: Increased striatal dopamine release in parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain Res 2009;132:1376-1385.
160.
Winstanley C, Cocker PJ, Rogers R: Dopamine modulates reward expectancy during performance of a slot machine task in rats: evidence for a ‘near-miss' effect. Neuropsychopharmacology 2011;36:913-925.
161.
O'Sullivan S, Evans AH, Lees AJ: Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009;23:157-170.
162.
Dalley J, Roiser J: Dopamine, serotonin and impulsivity. Neuroscience 2012;215:42-58.
163.
Chamberlain SR, Sahakian BJ: The neuropsychiatry of impulsivity. Curr Opin Psychiatry 2007;20:255-261.
164.
Boy F, Evans CJ, Edden RA, Lawrence AD, Singh KD, Husain M, Sumner P: Dorsolateral prefrontal gamma-aminobutyric acid in men predicts individual differences in rash impulsivity. Biol Psychiatry 2011;70:866-872.
165.
Cagnin A, Pompanin S, Manfioli V, Briani C, Zambon A, Saladini M, Dam M: Gamma-hydroxybutyric acid-induced psychosis and seizures. Epilepsy Behav 2011;21:203-205.
166.
Bennett W, Wilson LG, Roy-Byrne P: Gamma-hydroxybutyric acid (GHB) withdrawal: a case report. J Psychoactive Drugs 2007;39:293-296.
167.
Rosenberg M, Deerfield LJ, Baruch E: Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management. Am J Drug Alcohol Abuse 2003;29:487-496.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.